Acorn Cardiovascular completes financing:
This article was originally published in Clinica
Executive Summary
Acorn Cardiovascular, which is developing a device for heart failure patients, has completed a $24 million private placement. The St Paul, Minnesota company will use the funds to support clinical studies of its cardiac support device (CSD) (see Clinica No 916, p 15). The product is a mesh-like device that fits around the heart and is intended to halt the progression of the degenerative disease. The device is CE-marked and US clinical trials are under an FDA-approved investigational device exemption.